Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
3825 Comments
1015 Likes
1
Railyn
Legendary User
2 hours ago
If only I had checked this sooner.
👍 250
Reply
2
Gyan
Power User
5 hours ago
There has to be a community for this.
👍 109
Reply
3
Jaramy
Senior Contributor
1 day ago
I read this and now I feel different.
👍 275
Reply
4
Kadince
Returning User
1 day ago
Such focus and energy. 💪
👍 87
Reply
5
Aden
Expert Member
2 days ago
Comprehensive US stock historical volatility analysis and expected range projections for risk management. We provide volatility metrics that help you set appropriate stop-loss levels and position sizes.
👍 154
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.